Vnitr Lek 2016, 62(11):882-886

Hyperlipoproteinemia in children

Zuzana Urbanová
Klinika dětského a dorostového lékařství 1. LF UK a VFN v Praze

Hyperlipoproteinemia (HLP) is one of the most common metabolic disorder in childhood. We assume that 20 % of children have a disorder of the lipid metabolism. Some HLP are very common in the population, and moderate, and some are very rare, but are very severe. These may occur secondary to pathological conditions, or are formed on the basis of the primary monogenic or polygenic disorders of lipid metabolism. The detection of children with HLP in the Czech Republic is either random, or more often by selective screening of children with familial history of cardiovascular disease, provided by general pediatric practitioners for children and adolescents. Treatment in childhood is primarily dietetic, some of them, especially children with familial hypercholesterolemia are treated from 8-10 years pharmacologically.

Keywords: diagnosis; hyperlipoproteinemia; children; treatment

Received: September 22, 2016; Accepted: October 17, 2016; Published: November 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Urbanová Z. Hyperlipoproteinemia in children. Vnitr Lek. 2016;62(11):882-886.
Download citation

References

  1. Berenson GS, Srinivasan S, Bao W et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med 1998; 338(23): 1650-1656. Go to original source... Go to PubMed...
  2. Šamánek M, Urbanová Z. Prevence aterosklerózy v dětském věku. Galén: Praha 2003. ISBN 80-7262-229-3.
  3. Češka R. Diagnostika a léčba hyperlipoproteinémií. Triton: Praha 2003. ISBN 80-7254-328-8.
  4. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89(3):495-501. Go to original source... Go to PubMed...
  5. Urbanová Z, Šamánek M, Češka R et al. Doporučení pro diagnostiku a léčbu dyslipidemií u dětí a dospívajících, vypracované výborem České společnosti pro aterosklerózu. Cor et Vasa 2008; 50(2): K41-K47.
  6. Kavey RW, Stephen R, Lauer MR et al. American Heart Association Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood. Circulation 2003; 107(11): 1562-1566. Go to original source... Go to PubMed...
  7. Stephen R, Daniels MD, Gidding SS et al. Pediatric aspects of Familial Hypercholesterolemia: Recommendation from the National Lipid Association Expert Panel on Familial hypercholesterolemia. J Clin Lipidol 2011; 5(3 Suppl): S30-S37. Dostupné z DOI: <http://dx.doi.org/http://dx.doi.org/10.1016/j.jacl.2011.03.453>. Go to original source... Go to PubMed...
  8. Wiegman A, Gidding S, Wats GF et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36(36): 2425-37. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv157>. Go to original source... Go to PubMed...
  9. Bibbins-Domingo K, Grossman DC, Curry SJ et al. [US Preventive Services Task Force]. Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 316(6): 625-633. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.9852>. Go to original source... Go to PubMed...
  10. Urbanová Z, Freiberger T, Šamánek M et al. Komentář k souhrnu konsenzu panelu experů European Atherosclerotic Society k otázce optimalizace diagnostiky a léčby dětí s familiární hypercholesterolemií. Hypertenze a kardiovaskulární prevence 2016; 5(1): 36-38. Dostupné z WWW: <http://www.hypertension.cz/sqlcache/csh-01-2016-web.pdf>.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.